2019
DOI: 10.1038/s41573-019-0026-3
|View full text |Cite
|
Sign up to set email alerts
|

Aminoacyl-tRNA synthetases as therapeutic targets

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

3
210
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 200 publications
(226 citation statements)
references
References 187 publications
3
210
0
Order By: Relevance
“…In fact, the search for new therapeutic agents from the perspective of ARSs biology has received great attention 3,116,117 . These candidate agents mainly act on three aspects related to ARSs, including the catalytic sites of ARSs, the extracellular activities of secreted ARSs, and the proteins that interact with ARSs.…”
Section: Conclusion and Future Perspectivementioning
confidence: 99%
See 1 more Smart Citation
“…In fact, the search for new therapeutic agents from the perspective of ARSs biology has received great attention 3,116,117 . These candidate agents mainly act on three aspects related to ARSs, including the catalytic sites of ARSs, the extracellular activities of secreted ARSs, and the proteins that interact with ARSs.…”
Section: Conclusion and Future Perspectivementioning
confidence: 99%
“…Finally, the resulting aminoacylated tRNA enters the ribosome during messenger RNA (mRNA) translation. Each ARS molecule and its encoding gene are named in the form of XRS and XARS, respectively, where X represents the single-or three-letter code of the cognate amino acid 3 . To date, 36 ARSs encoded by different genes have been found in human cells, catalyzing the aminoacylation of all tRNAs 4,5 .…”
Section: Introductionmentioning
confidence: 99%
“…On the other hand, the upregulation of aaRSs, including YARS, was observed in several types of cancer (Guo et al 2010;Hsu et al 2019), while polymorphisms in aaRS genes were reported to be associated with breast cancer risk (He et al 2015). Emerging studies also implicated the involvement of aaRSs with multiple pathway networks through constituting the multi-tRNA synthetase complex (MSC) (Hyeon et al 2019) and raised the possibility of aminoacyl-tRNA synthetases as therapeutic targets against autoimmune diseases, rare diseases, and even cancer (Kwon et al 2019). Nevertheless, although abundantly exists and functions in all organisms, YARS's actual linkage with cancer remains unspecified.…”
Section: Introductionmentioning
confidence: 99%
“…However, the role of EPRS in cardiac disease is still unexplored. Besides, an (E)PRS-specific inhibitor, halofuginone (Halo), blocks binding of (E)PRS to proline and tRNA Pro and prevents their ligation [12][13][14] . Halo has been used to treat Duchenne Muscular Dystrophy (DMD) (Akashi Therapeutics) by reducing fibrosis and increasing muscle strength in phase II clinical trials.…”
Section: Introductionmentioning
confidence: 99%